IVD solutions through partnership

Mast Group

CHROMagar™ MRSA

For isolation and differentiation of Methicillin Resistant *Staphylococcus aureus* (MRSA) including low level MRSA

CHROMagar™

The Chromogenic Media Pioneer

CHROMagar™ MRSA

For isolation and differentiation of Methicillin Resistant *Staphylococcus aureus* (MRSA) including low level MRSA

Plate Reading

- Methicillin Resistant *Staphylococcus aureus* (MRSA) → rose to mauve
- Methicillin Susceptible *Staphylococcus aureus* (MSSA) → inhibited
- Other bacteria → blue, colourless or inhibited



Background

Leading cause of nosocomial infections, especially in intensive care units, the MRSA sources are either endogenous (the patient) or through cross contamination (environmental or by person to person contact).
The major issue with this pathogen is its resistance to a large panel of antibiotics, among them beta-lactam antibiotics, limiting the therapeutic options for clinicians.
Early detection is essential for controlling the spread of MRSA, providing appropriate care, and avoiding complex and expensive treatments. Pre-admission screening for MRSA has proved to be an effective method for reducing the hospital burden of MRSA-colonised patients. The savings due to consistent decolonisation before elective admission outweigh the costs of screening. Today, in the US, the extra-expenses linked to difficult treatments of MRSA infections are estimated at $2.4 billion for about 370,000 hospital stays. (Genetic Engineering and Biotechnology News, August 2009).
In the UK, the estimation of the additional cost of discharging every hospital patient who acquires MRSA is £9,000.

Medium Performance

1. **Absolutely reliable**
CHROMagar™ MRSA, introduced in 2002, was the first chromogenic medium for MRSA detection. It lead to such significant reductions in both, the response time and laboratory workload, that it allowed an absolutely necessary wide-scale patient screening.

2. **Efficient**
The medium exhibits sensitivity and specificity values close to 100%.
CHROMagar™ MRSA allows an accurate detection of MRSA with a higher level of sensitivity than oxacillin containing media.

3. **Fast & easy interpretation**
Intense mauve → colour in 18-24h.

Medium Description

Powder Base	Total .....82.5 g/L Agar .....15.0 Peptones and yeast extract.....40.0 Salts .....25.0 Chromogenic mix .....2.5 Storage at 15/30 °C - pH: 6.9 +/-0.2 Shelf Life ..... > 18 months
+ **Supplement** (included in the pack)	Powder form qsf 20 L .....20 mL Storage at 2/8 °C Shelf Life .... > 18 months

Usual Samples	nasal, perineal, throat, rectal specimens
Procedure	Direct Streaking. Incubation 18-24 h at 35-37 °C. Aerobic conditions
Scientific Publications on this product: available on www.CHROMagar.com Please read carefully the instructions for use (IFU document) available on www.CHROMagar.com	

IVD CE

Manufacturer:
CHROMagar
4 place du 18 juin 1940 75006 Paris - France
e-mail: CHROMagar@CHROMagar.com
www.CHROMagar.com

Version 8.0 / Jul-20 (Mast)
LF-EXT-014

Distributed by:
Mast Diagnostica GmbH
Feldstraße 20
DE-23858 Reinfeld

Tel: +49 (0)4533 2007 0
Fax: +49 (0)4533 2007 68
e-mail: mast@mast-diagnostica.de
www.mast-group.com

Ordering Information

Product	Order Code
CHROMagar™ MRSA dry media, 5 liter	15MR502
CHROMagar™ MRSA ready to use plates, 20 pcs.	201402